Related Experiment Video
Updated: Aug 24, 2025
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)
Haris Hatic1, Shealeigh Inselman2, Jonathan Inselman2
1Department of Hematology-Oncology, University of Alabama, 2000 6th Ave S, Birmingham, AL 35233, USA.
Introduction:
Multiple myeloma (MM) is an incurable plasma cell neoplasm. In this study, we aimed to analyze the impact of time to initiation of systemic therapy for MM on overall survival (OS).
Methods:
We identified cases diagnosed with MM from the National Cancer Database from 2004 to 2013.
Results:
A total of 38,178 MM patients were included in the analysis. The median time to systemic therapy in our cohort was 17 days (range 0-120). The median OS for patients who initiated therapy > 30-days after diagnosis was longer than those who received it ≤ 7 days (46 vs. 27-month, p < 0.001). On multivariable analysis, patients who received treatment ≤ 7 days from diagnosis had worse mortality compared with those receiving treatment > 30 days (HR 1.5; 95% CI 1.4-1.6).
Conclusions:
In our study, time to initiation of systemic therapy was an independent prognostic factor in MM. Similar to other lymphoid malignancies, this metric may be a surrogate for high-risk disease in MM, and future trials may need to investigate time-to-treatment as a factor to allow enrollment of potentially sick patients.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...